Ultragenyx Pharmaceutical | RARE - Market Capitalization


Ultragenyx Pharmaceutical reported $2.06B in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.77B 745M May/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
BioMarin Pharmaceutical USD 10.57B 290M May/2026
Esperion Therapeutics USD 885M 351M Dec/2025
Immunic USD 64M 23M Dec/2025
Insmed USD 37.12B 6.68B Dec/2025
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Karyopharm Therapeutics USD 956M 821M May/2026
Kyowa Hakko Kirin JPY 1.33T 120.11B Dec/2025
MacroGenics USD 102M 4M Dec/2025
Moderna USD 20.15B 8.53B Mar/2026
Neurocrine Biosciences USD 13.44B 189M May/2026
PTC Therapeutics USD 6.1B 1.22B Dec/2025
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Sarepta Therapeutics USD 2.04B 210M May/2026
Ultragenyx Pharmaceutical USD 2.06B 1000K May/2026
Vertex Pharmaceuticals USD 111.03B 2.55B May/2026